Are Analysts Bearish Cesca Therapeutics Inc. (NASDAQ:KOOL) After Last Week?

January 13, 2018 - By Vivian Currie

 Are Analysts Bearish Cesca Therapeutics Inc. (NASDAQ:KOOL) After Last Week?

Cesca Therapeutics Inc. (NASDAQ:KOOL) Ratings Coverage

Among 2 analysts covering Cesca Therapeutics (NASDAQ:KOOL), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Cesca Therapeutics had 4 analyst reports since August 25, 2015 according to SRatingsIntel. The firm has “Buy” rating by Maxim Group given on Tuesday, November 17. H.C. Wainwright upgraded the stock to “Buy” rating in Monday, September 21 report. As per Tuesday, August 25, the company rating was upgraded by Zacks. The firm has “Hold” rating given on Tuesday, December 22 by Maxim Group. Below is a list of Cesca Therapeutics Inc. (NASDAQ:KOOL) latest ratings and price target changes.

The stock decreased 1.89% or $0.0605 during the last trading session, reaching $3.1395. About 99,309 shares traded. Cesca Therapeutics Inc. (NASDAQ:KOOL) has declined 16.34% since January 13, 2017 and is downtrending. It has underperformed by 33.04% the S&P500.

Cesca Therapeutics Inc. focuses on the research, development, and commercialization of autologous cell therapeutics for use in regenerative medicine in the United States and internationally. The company has market cap of $34.11 million. The firm develops and makes automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. It currently has negative earnings. The Company’s products include SurgWerks system, a proprietary system comprised of the SurgWerks processing platform, including devices and analytics, and indication-specific SurgWerks procedure kits for use in regenerative stem cell therapy at the point of care for vascular and orthopedic diseases; CellWerks system, a proprietary cell processing system with associated analytics for intra-laboratory preparation of adult stem cells from bone marrow or blood; and AutoXpress system, a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood.

More notable recent Cesca Therapeutics Inc. (NASDAQ:KOOL) news were published by: Sacbee.com which released: “Cesca Therapeutics subsidiary acquires assets of Sacramento’s SynGen Inc.” on July 10, 2017, also Globenewswire.com with their article: “Cesca Therapeutics Announces Issuance of Second Cellular Processing Patent” published on November 28, 2017, Seekingalpha.com published: “Cesca Therapeutics (KOOL) Q3 2017 Results – Earnings Call Transcript” on May 12, 2017. More interesting news about Cesca Therapeutics Inc. (NASDAQ:KOOL) were released by: Seekingalpha.com and their article: “Cesca Therapeutics’ (KOOL) Management on Q4 2017 Results – Earnings Call …” published on September 20, 2017 as well as Reuters.com‘s news article titled: “BRIEF-Cesca Therapeutics Announces Proposed Public Offering Of Common Stock” with publication date: November 28, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.